Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.
Rolle des perilesionalen Ödems und des Tumorvolumens bei der Prognose von nicht-kleinzelligem Lungenkrebs (NSCLC) nach einer Radiochirurgie (SRS) von Hirnmetastasen.
Aged
Aged, 80 and over
Brain Edema
/ diagnostic imaging
Brain Neoplasms
/ diagnostic imaging
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Chemotherapy, Adjuvant
Cohort Studies
Combined Modality Therapy
Disease Progression
Female
Follow-Up Studies
Humans
Immunotherapy
Lung Neoplasms
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Middle Aged
Prognosis
Radiosurgery
Survival Rate
Tumor Burden
/ radiation effects
Brain metastases
Non-small cell lung cancer
Perilesional edema
Stereotactic radiosurgery
Tumor volume
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
11
01
2019
accepted:
10
05
2019
pubmed:
28
5
2019
medline:
13
2
2020
entrez:
25
5
2019
Statut:
ppublish
Résumé
To assess the role of perilesional edema (PE) in non-small cell lung carcinoma (NSCLC) brain metastases (BM) undergoing radiosurgery (SRS). This series includes 46 patients with 1-2 BM treated with SRS, selected out of all patients referred for radiotherapy (RT) for BMs over 5 years (2013 to 2017). Both the PE and gross tumor volume (GTV) were contoured on MRI images, and the PE/GTV ratio and PE + GTV value (TV, total volume) were calculated. Our clinical endpoints were brain recurrence free-survival, divided into local brain control (in field, LBC) and distant brain control (out of field, DBC) and overall survival (OS). We analyzed the role of the previously described volumetric parameters and of known clinical prognosticators (disease specific GPA, DS-GPA; chemotherapy, CHT) with Cox regression analyses. Only four patients (9%) developed in-field progression, whereas 10 patients (22%) showed new out-of-field BM and thirty-eight patients died in the follow up (83%). In univariate analysis, both volumetric parameters and clinical parameters were correlated with DBC and OS, whereas we did not find any correlation with LBC. In the multivariate analysis of DBC, the significant parameters were PE/GTV ratio (HR 0.302), sex (HR 0.131), and DS-GPA (HR 0.261). The OS multivariate analysis showed that the only significant parameters were DS-GPA (HR 0.478) and TV (HR: 1.038). Our study, although with the limitations of a monocentric retrospective study analyzing a small cohort of patients, suggests the role of PE/GTV ratio for the development of new BMs. TV also seems to be correlated with OS, together with known clinical prognosticators. These findings, if validated in a larger prospective dataset, could help in selecting patients for the most suitable RT modality (or systemic therapy approach).
Identifiants
pubmed: 31123785
doi: 10.1007/s00066-019-01475-0
pii: 10.1007/s00066-019-01475-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
734-744Références
J Neurosurg. 2013 Nov;119(5):1139-44
pubmed: 23971958
Anticancer Res. 2000 Jan-Feb;20(1A):305-10
pubmed: 10769672
Eur J Neurol. 2009 Jul;16(7):874-8
pubmed: 19473360
Transl Oncol. 2018 Oct;11(5):1119-1127
pubmed: 30032006
Oncoimmunology. 2015 Jun 9;5(1):e1057388
pubmed: 26942067
Transl Lung Cancer Res. 2016 Dec;5(6):610-627
pubmed: 28149756
Clin Lung Cancer. 2014 Sep;15(5):346-55
pubmed: 24894943
Int J Surg. 2016 Sep;33 Suppl 1:S148-53
pubmed: 27392721
Nat Med. 2018 Jul;24(7):1024-1035
pubmed: 29892069
Anticancer Res. 2016 Oct;36(10):5333-5337
pubmed: 27798896
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1122-7
pubmed: 20638188
Chin Clin Oncol. 2015 Jun;4(2):18
pubmed: 26112804
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Pract Radiat Oncol. 2013 Apr-Jun;3(2):101-6
pubmed: 24674312
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Radiother Oncol. 2015 Nov;117(2):315-21
pubmed: 26347495
JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
Expert Rev Anticancer Ther. 2018 Jun;18(6):593-602
pubmed: 29582686
Neurol Sci. 2017 Jun;38(6):975-982
pubmed: 28260188
Clin Exp Metastasis. 2013 Apr;30(4):357-68
pubmed: 23076770
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):656-61
pubmed: 22898384
Int J Surg. 2016 Sep;33 Suppl 1:S126-31
pubmed: 27353845
FASEB J. 2017 Nov;31(11):5049-5067
pubmed: 32083386
CNS Oncol. 2014 Jan;3(1):61-75
pubmed: 25054901
Neuropathol Appl Neurobiol. 2001 Oct;27(5):384-95
pubmed: 11679090
Glia. 1999 Oct;28(1):40-8
pubmed: 10498821
Support Care Cancer. 2016 Feb;24(2):523-528
pubmed: 26105515
Front Oncol. 2018 Oct 09;8:415
pubmed: 30356657
Strahlenther Onkol. 2014 Jul;190(7):676-85
pubmed: 24577133
J Neurosurg. 2008 Dec;109 Suppl:77-86
pubmed: 19123892
Lancet Respir Med. 2017 Sep;5(9):707-716
pubmed: 28734822
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Front Oncol. 2018 May 24;8:161
pubmed: 29881714
Cancer Imaging. 2014 Apr 22;14:8
pubmed: 25608557
Radiother Oncol. 2018 Oct;129(1):183-184
pubmed: 29331541
Radiat Oncol. 2017 Jun 26;12(1):107
pubmed: 28651600
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):898-903
pubmed: 16338097
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Lancet. 2016 Oct 22;388(10055):2004-2014
pubmed: 27604504
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1394-8
pubmed: 22209150
Am J Clin Oncol. 2013 Oct;36(5):486-90
pubmed: 22706180
Front Immunol. 2018 Dec 12;9:2941
pubmed: 30619301
Eur J Cancer. 2018 Apr;93:37-46
pubmed: 29477100
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):655-61
pubmed: 19942357
J Radiat Res. 2018 Jan 1;59(1):43-49
pubmed: 29069502
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1312-8
pubmed: 23391814
J Thorac Oncol. 2017 Oct;12(10):1467-1477
pubmed: 28733269
Neuroscience. 2004;129(4):1011-20
pubmed: 15561416
Cancer Med. 2018 Mar;7(3):757-764
pubmed: 29441722
J Clin Oncol. 2018 Feb 10;36(5):483-491
pubmed: 29272161